Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy

British Journal of Ophthalmology

Volumn 94, Issue 7, 2010, Pages 858-863

  Cho, Won Bin ^a   Moon, Jun Woong ^a   Kim, Hyung Chan ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; CATARACT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAOCULAR; LASER COAGULATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY; YOUNG ADULT;

EID: 77954285140     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.168997     Document Type: Article

References (32)

1. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS): DRS report 8. Ophthalmology 1981;88:583-600.
2. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85.
3. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-56.
4. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina 1985;5:5-10. (Pubitemid 15120379)
5. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985;92:388-93. (Pubitemid 15099102)
6. Higgins KE, Meyers SM, Jaffe MJ, et al. Temporary loss of foveal contrast sensitivity associated with panretinal photocoagulation. Arch Ophthalmol 1986;104:997-1003.
7. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS Report number 2. Ophthalmology 1991;98:766-86.
8. Aiello LM, Cavallerano J, Aiello LP. Diagnosis, management and treatment of nonproliferative diabetic retinopathy and macular edema. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd edn. Philadelphia: WB Saunders, 2000:1900-14.
9. Nonaka A, Kiryu J, Tsujikawa A, et al. Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 2002;43:1204-9.
10. Tsujikawa A, Kiryu J, Dong J, et al. Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer. Retina 1999;19:59-64.
11. Funatsu H, Yamashita H, Ikeda T, et al. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003;135:321-7.
12. Del Maschio A, Zanetti A, Corada M, et al. Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 1996;135:497-510.
13. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-7.
14. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
15. Zein WM, Noureddin BN, Jurdi FA, et al. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina 2006;26:137-42.
16. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-50.
17. Jonas JB, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-5.
18. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-43.
19. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-40.
20. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6.
21. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
22. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-13.
23. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
24. Cho WB, Moon JW, Kim HC, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29:516-22.
25. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-9.
26. Mason JO 3rd, Yunker JJ, Vail R, et al. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008;28:1319-24.
27. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-9. (Pubitemid 351692187)
28. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
29. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-61.
30. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology 2004;111:2044-9.
31. Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS Report No. 3. Int Ophthalmol Clin 1987;27:254-64.
32. Vander JF, Duker JS, Benson WE, et al. Longterm stability and visual outcome after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991;98:1575-9.